EXANE DERIVATIVES - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 278 filers reported holding SAGE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q2 2022$452,000
-2.4%
140.0%0.00%
Q1 2022$463,000
-22.3%
140.0%0.00%
Q4 2021$596,000
-3.9%
140.0%0.00%
Q3 2021$620,000
-97.0%
14
-96.4%
0.00%
-100.0%
Q2 2021$20,459,000
-29.9%
3900.0%0.01%
-37.5%
Q1 2021$29,190,000
-13.5%
3900.0%0.01%
-20.0%
Q4 2020$33,737,000
+9092.6%
390
+6400.0%
0.01%
Q3 2020$367,000
+47.4%
60.0%0.00%
Q2 2020$249,000
+44.8%
60.0%0.00%
Q1 2020$172,000
-61.7%
60.0%0.00%
Q4 2019$449,000
-46.7%
60.0%0.00%
Q3 2019$842,000
-23.3%
60.0%0.00%
Q2 2019$1,098,000
+15.1%
60.0%0.00%
Q1 2019$954,000
+65.9%
60.0%0.00%
Q4 2018$575,000
-31.1%
60.0%0.00%
Q3 2018$834,000
-99.2%
6
-99.1%
0.00%
-100.0%
Q2 2018$103,215,000
-0.1%
6620.0%0.02%
-19.0%
Q1 2018$103,305,0006620.02%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,966,688$120,204,00010.81%
Integral Health Asset Management, LLC 230,000$14,058,0004.30%
Asymmetry Capital Management, L.P. 102,462$6,262,0004.02%
ACUTA CAPITAL PARTNERS, LLC 225,000$13,752,0003.74%
DAFNA Capital Management LLC 158,306$9,676,0003.14%
Bain Capital Life Sciences Investors, LLC 499,100$30,505,0002.84%
Boxer Capital, LLC 1,094,000$66,865,0002.31%
Palo Alto Investors LP 590,200$36,073,0001.98%
Logos Global Management LP 250,000$15,280,0001.96%
Bellevue Group AG 1,579,504$96,539,0001.33%
View complete list of SAGE THERAPEUTICS INC shareholders